arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Lite Strategy, Inc.

LITS
$0.91 ▼ -0.05 (-4.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lite Strategy, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $32.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -30.0%
FCF / Share $-0.04
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-3.64M
↑ +54.6%
Operating Margin Operating profit as % of sales
84.7%
↑ +130.4%
FCF / Share Free cash flow per share
$-0.04
↑ +17.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
76

Dividend History

Dividend / share · sourced from SEC filings
$1.75 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 24 years · 72 quarters